Single and Multi-color reference plates now available for verifying ImmunoSpot® instrument’s consistent performance: Instrument qualification and validation has never been simpler.
Confirm instrument performance with a reference plate and dedicated ImmunoQualify software – generate Pass/Fail reports with a click of a button.
All CTL instruments now can count ELISPOT results consistently: Harmonization of instruments among different sites has never been more simple
Our IntelliCount software uses spot recognition criteria that are independent of some of the variables commonly affecting classical counting results such as differences in light sources, optics and other image capture components . This
software is a major step towards elevating ELISpot to an exact science by coming up with consistent/standardized counts.
Not just the first choice for ELISPOT/FluoroSpot and serum neutralization assays in general: ImmunoSpot® Instruments have also become the gold standard for reading SARS-CoV-2
antibody neutralization.
All fluorescence-capable ImmunoSpot® analyzers now come with high-throughput live/dead PBMC counting capability
Live/dead cell counting is important for the assessment of PBMC samples’ fitness following cryopreservation or prolonged storage/shipment [ref]. The accurate counting of live cells in PBMC is essential for adjusting the cell numbers to
be plated into ELISPOT/FluoroSpot assays as divergent cell counts contribute the largest variability to inter-assay reproducibility. Unless using a dedicated instrument for live/dead cell counting, this process is time-consuming and rate
limiting for testing of multiple PBMC samples in an experiment. No longer!
ImmunoSpot® analyzers now permit measuring cell-mediated cytotoxicity via the Target Cell Visualization Assay (TVA)
Measuring cell-mediated cytotoxicity is part of the assay repertoire of most laboratories involved in immune monitoring efforts. CTL’s philosophy is to offer instruments that support several functions commonly performed in immune
monitoring laboratories. Enabled by our TVA Software suite, CTL’s fluorescence capable ImmunoSpot® instruments can measure cell-mediated cytotoxicity.
New ImmunoSpot® Release: SpotStat™ Software for the statistical analysis of ELISPOT/FluoroSpot data
The primary function of SpotStat® is to provide statistically-validated discrimination between antigen-induced responses and negative controls. SpotStat® was specifically designed to perform multiple comparison tests using a number of
family-wise error correction methods, when multiple positive responses (e.g. peptide screening in T cell assays) are compared to a single negative control for the same subject (donor).
ImmunoSpot® kit plates now available with precoating quality controlled
Membranes of PVDF plates suited for ELISPOT/FluoroSpot analysis can show regional defects that can cause individual wells to fail. No longer! At CTL, for our ImmunoSpot® kits we now quality control the membrane of each well, and we
devised ways to quality control the even pre-coating of each well, in addition.
Looking for positive/negative control PBMC reference samples? In addition to offering PBMC that have defined numbers of antigen-specific T cells, we now also offer PBMC with defined numbers of antigen-specific B cells.
Access to custom antigen-specific B cell ImmunoSpot® assays
The primary limitation to developing new antigen-specific B cell ELISPOT/FluoroSpot assays has been the ability to coat membranes densely with antigen. No longer!
CTL introduces new HDR imaging platform for FluoroSpot analysis
Conventional FluoroSpot relies on the analysis of a single image of a well, captured using a single exposure level. This approach may miss faint spots, while overly bright spots can be over-exposed, leading to inaccurate quantitation of
the per cell secretory activity. No longer!
CTL scientists highlight ImmunoSpot®’s suitability for high-throughput immune monitoring
Our recent publication details how comprehensive ImmunoSpot® testing against all potential determinants of an antigen is technically feasible, and calls into question the usage of single or few previously established or predicted
peptides for reliable immune monitoring.